Your browser doesn't support javascript.
loading
A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report.
Cioboata, M; Alexandrescu, C; Hopinca, C A; Pienaru, M C; Merticariu, A; Schmitzer, S.
Afiliação
  • Cioboata M; Clinical Emergency Eye Hospital, Bucharest, Romania.
  • Alexandrescu C; Department of Ophthalmology, University Hospital, Bucharest.
  • Hopinca CA; Clinical Emergency Eye Hospital, Bucharest, Romania.
  • Pienaru MC; Clinical Emergency Eye Hospital, Bucharest, Romania.
  • Merticariu A; Clinical Emergency Eye Hospital, Bucharest, Romania.
  • Schmitzer S; Clinical Emergency Eye Hospital, Bucharest, Romania.
J Med Life ; 9(1): 92-94, 2016.
Article em En | MEDLINE | ID: mdl-27713772
ABSTRACT
We report the case of a 46-year-old patient, medical doctor with a relapsing unilateral CRSC-Central Serous Chorioretinopathy who was treated after an initial medical therapy (oral carbonic anhydrase inhibitor, oral antihistamines, non-steroidal anti-inflammatory drugs - systemic and topical), with an oral aldosterone antagonist-Eplerenone (Inspra), resulted in significant anatomic and visual improvements. Abbreviations CRSC = Central Serous Chorioretinopathy, R.E. = right eye, L.E. = left eye, BCVA = best corrected visual acuity, RPE = retinal pigment epithelium, OCT = optical coherence tomography, FDA = food and drug administration.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Espironolactona / Antagonistas de Receptores de Mineralocorticoides / Coriorretinopatia Serosa Central Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Espironolactona / Antagonistas de Receptores de Mineralocorticoides / Coriorretinopatia Serosa Central Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article